6E3L
Interferon gamma signalling complex with IFNGR1 and IFNGR2
Summary for 6E3L
Entry DOI | 10.2210/pdb6e3l/pdb |
Related | 6E3K |
Descriptor | Interferon gamma, Interferon gamma receptor 1, Interferon gamma receptor 2, ... (8 entities in total) |
Functional Keywords | cytokine receptor, protein complex, protein engineering, cytokine |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 6 |
Total formula weight | 147235.68 |
Authors | Jude, K.M.,Mendoza, J.L.,Garcia, K.C. (deposition date: 2018-07-14, release date: 2019-02-27, Last modification date: 2024-10-23) |
Primary citation | Mendoza, J.L.,Escalante, N.K.,Jude, K.M.,Sotolongo Bellon, J.,Su, L.,Horton, T.M.,Tsutsumi, N.,Berardinelli, S.J.,Haltiwanger, R.S.,Piehler, J.,Engleman, E.G.,Garcia, K.C. Structure of the IFN gamma receptor complex guides design of biased agonists. Nature, 567:56-60, 2019 Cited by PubMed Abstract: The cytokine interferon-γ (IFNγ) is a central coordinator of innate and adaptive immunity, but its highly pleiotropic actions have diminished its prospects for use as an immunotherapeutic agent. Here, we took a structure-based approach to decoupling IFNγ pleiotropy. We engineered an affinity-enhanced variant of the ligand-binding chain of the IFNγ receptor IFNγR1, which enabled us to determine the crystal structure of the complete hexameric (2:2:2) IFNγ-IFNγR1-IFNγR2 signalling complex at 3.25 Å resolution. The structure reveals the mechanism underlying deficits in IFNγ responsiveness in mycobacterial disease syndrome resulting from a T168N mutation in IFNγR2, which impairs assembly of the full signalling complex. The topology of the hexameric complex offers a blueprint for engineering IFNγ variants to tune IFNγ receptor signalling output. Unexpectedly, we found that several partial IFNγ agonists exhibited biased gene-expression profiles. These biased agonists retained the ability to induce upregulation of major histocompatibility complex class I antigen expression, but exhibited impaired induction of programmed death-ligand 1 expression in a wide range of human cancer cell lines, offering a route to decoupling immunostimulatory and immunosuppressive functions of IFNγ for therapeutic applications. PubMed: 30814731DOI: 10.1038/s41586-019-0988-7 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.8 Å) |
Structure validation
Download full validation report